



Figure 1

Dox: doxorubicin. Tol: tolvaptan. Veh: vehicle.

Kaplan-Meier Survival Analysis of tolvaptan-treated rats.

Figure 2


Dox: doxorubicin. Tol: tolvaftan. Veh: vehicle.

Figure 3

Day	-3	-2	-1	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Dox																		
Dox+DDAVP																		
Feeding																		

Protocol for the DDAVP study

Dox: doxorubicin.


Figure 4

Dox: doxorubicin.


Kaplan-Meier survival analysis of doxorubicin treated rats.

Figure 5

Blood sampling protocol



- Dox: doxorubicin 2.5 mg/kg intraperitoneal injection 20 min prior to Veh or Tol
- Tol: tolvaptan 10 mg/kg. Veh: vehicle 1 % hydroxypropylmethylcellulose
- Heparinized Blood samples withdrawn 20 min after Tol or Veh on day 1 or day 13.

Figure 6

Veh: vehicle, Tol: tolvaptan




Figure 7


Figure 8

Tox: tolvaptan. Dox: doxorubicin. Veh: vehicle.

Figure 9


Dox: doxorubicin. Veh: vehicle.

Ejection Fraction of the Left Ventricle

Figure 10


Tox: tolvaptan. Dox: doxorubicin. Veh: vehicle.

Left ventricle end-diastolic volume/weight adjusted.

Figure 11

Tol: tolvaptan. Dox: doxorubicin. Veh: vehicle.

Left ventricle end-diastolic diameter/weight adjusted.

Figure 12

Tol: tolvaptan. Dox: doxorubicin. Veh: vehicle.

Improvement of Contractility Index

Figure 13

Protocol





Figure 14

Tol: tolvaaptan. Dox: doxorubicin. $p < 0.02$ when the survival rates were compared using the Log-Rank test.

Kaplan Meier Survival Analysis.